During
thrombosis, vascular wall cells are exposed to
clotting factors, including the procoagulant
proteases thrombin and
factor Xa (FXa), both known to induce cell signaling. FXa shows dose-dependent induction of intracellular Ca(2+) transients in vascular wall cells that is active-site-dependent, Gla-domain-independent, and enhanced by FXa assembly into the
prothrombinase complex. FXa signaling is independent of
prothrombin activation as shown by the lack of inhibition by
argatroban,
hirudin and the sulfated C-terminal
peptide of
hirudin (Hir(54-65)(SO3(-))). This
peptide binds to both proexosite I in
prothrombin and exosite I in
thrombin. In contrast, signaling is completely blocked by the FXa inhibitor
ZK-807834 (CI-1031). No inhibition is observed by
peptides which block interaction of FXa with effector cell
protease 1 receptor (EPR-1), indicating that this receptor does not mediate signaling in the cells assayed. Receptor desensitization studies with
thrombin or
peptide agonists (PAR-1 or PAR-2) and experiments with PAR-1-blocking
antibodies indicate that signaling by FXa is mediated by both PAR-1 and PAR-2. Potential pathophysiological responses to FXa include increased cell proliferation, increased production of the proinflammatory
cytokine IL-6 and increased production of prothrombotic
tissue factor. These cellular responses, which may complicate
vascular disease, are inhibited by
ZK-807834.